

Fig. 1a–d. Localization of lymphoid cell aggregations (lymphocyte-filled villi, LFVs) in the hematoxylin-and-eosin-stained tissue sections of small intestine from 13-day-old (a and b) and 7-week-old (c and d) Wistar rats

ther, small-intestinal villi containing LFVs were thicker than other villi (see below). We next examined small-intestinal mucosa from 7-week-old young adult rats, and found that lymphoid cell clusters were localized throughout the small-intestinal mucosa (Fig. 1c, d). It was also verified that about 1600 of such lymphoid cell clusters were present in 7-week-old young adult rats, and that these clusters were also morphologically classified as LFVs by H&E staining (data not shown). We analyzed extensively the small intestine from three 10-week-old rats and noted that LFVs were not evenly distributed in the small-intestinal mucosa. The average number of LFVs in the duodenum and jejunum was 1.6 ± 0.2 and $1.1 \pm 0.1/100$ villi, compared to $0.2 \pm 0.1/100$ villi ($P < 0.005$) in the distal half of the ileum.

Neither CPs nor ILFs were detected in the small intestine of fetal mice. In mice, CPs can be first detected at 14–17 days after birth,³ and ILFs can be first detected at 7 (BALB/c mice) and 25 (C57BL/6 mice) days after birth.¹⁵ We therefore investigated the development of LFVs in the Wistar rats, and found that LFVs could not be detected in fetal and neonatal rats, but became detectable without exception by 13 days after birth (Fig. 1a, b). These findings clearly indicate that rat LFVs develop after birth, like mouse CPs and ILFs.

Mayrhofer and Brooks¹⁰ stated that, because LFVs contain few mature T and B cells, they represent organized GALTs populated mainly by undifferentiated lymphocytes. With this possibility in mind, we aimed to investigate whether rat LFVs consisted of clusters of undifferentiated lymphocytes, like mouse CPs. Rat LFVs were immunohistochemically stained for c-kit, a marker for undifferentiated lymphocytes, and examined under microscopy. Rat LFVs were found to contain numerous c-kit⁺ cells (Fig. 2a, c). Furthermore, the




Fig. 2a–d. Immunohistochemical visualization of a and c c-kit⁺ and b and d interleukin 7 receptor (*IL-7R*)⁺ lymphocytes in small-intestinal LFVs from 13-day-old (a and b) and 7-week-old (c and d) Wistar rats

rat LFVs were immunohistochemically stained for IL-7R, a cell-surface antigen found on mouse CP cells, revealing that rat LFVs also contained numerous IL-7R-expressing lymphocytes (Fig. 2b, d). These findings suggest that, as claimed by Mayrhofer and colleagues,⁹ LFVs represent CP-like lymphoid tissues consisting of clusters of undifferentiated cells expressing c-kit and IL-7R. Next, to analyze the lymphoid cells forming rat LFVs in greater detail, we explored the expression of various cell-surface antigens.

The distribution of B cells in LFVs was immunohistochemically analyzed using antibody to rat IgM, and it was revealed that LFVs could be divided into those with and without IgM⁺ cells (IgM⁺ and IgM⁻ LFVs, respectively; Fig. 3b–d). Most IgM⁺ LFVs were arranged linearly on the antimesenteric wall (Fig. 3b, c), and numbered about 400 in small intestine from 7-week-old rats. IgM⁻ LFVs were found throughout the intestinal mucosa (Fig. 3b, d), and numbered about 1200 in small intestine from 7-week-old rats, although fewer IgM⁻ LFVs were present at the end of the ileum (data not shown). A small number of $\alpha\beta$ ⁺ T cells was interspersed among both IgM⁺ and IgM⁻ LFVs (Fig. 3f–h). On vertical sections of LFVs, IgM⁺ B cells were found to occupy the core and the base of villi (Fig. 4a), whereas $\alpha\beta$ ⁺ T cells were distributed mainly over the upper half of both IgM⁺ and IgM⁻ LFVs (Fig. 4b, f). On the basis of these vertical profiles, it was also evident that LFVs were thicker than surrounding villi that were devoid of lymphocyte congregation (Fig. 4a–h) and that both IgM⁺ and IgM⁻ LFVs were filled with closely packed c-kit⁺ (Fig. 4c, g) and IL-7R⁺ (Fig. 4d, h) lymphocytes.

To confirm that LFVs found on the antimesenteric wall of the small intestine contained B cells, we located an LFV under a transillumination stereomicroscope




Fig. 3a-h. Immunohistochemical visualization of **a, b, c, d** IgM⁺ **e, f, g, h** T cell receptor (TCR)- $\alpha\beta$ ⁺ lymphocytes in Peyer's patches (PPs) and LFVs. Frozen sections of small intestine from 7-week-old Wistar rats were prepared, and PP (**a** and **e**) and LFV (**b** and **f**) were immunohistochemically analyzed. Consecutive tissue sections were stained with anti-IgM (**a** and **b**) and anti-TCR- $\alpha\beta$ (**e** and **f**) monoclonal antibody (mAb), respectively. Multiple LFVs are aligned along the antimesenteric wall of the mucosa (*arrowheads*) and LFVs are also interspersed throughout the mucosa. Magnified views of the representative LFVs are also presented (**c, d, g, f**)




Fig. 4a-h. Immunohistochemical characterizations of **a, b, c, d** IgM⁺ and **e, f, g, h** IgM⁻ LFVs in consecutive longitudinal tissue sections of small intestine from 7-week-old Wistar rats. IgM⁺ cells are found on the bottom of IgM⁺ LFV (**a**), but IgM⁻ LFV lacks such IgM⁺ cells (**e**) (*arrows*). $\alpha\beta$ T cells tend to be localized in the subepithelial regions of both IgM⁺ (**b**) and IgM⁻ (**f**) LFVs. Numerous c-kit⁺ cells are present in both IgM⁺ (**c**) and IgM⁻ (**g**) LFVs, and numerous IL-7R⁺ cells are also present in both IgM⁺ (**d**) and IgM⁻ (**h**) LFVs




Fig. 5. Flow cytometric analysis of lymphocytes isolated from IgM⁺ and IgM⁻ LFVs. Lymphocytes were isolated from LFVs of 7-week-old Wistar rats and stained using anti-IgM and anti-TCR- $\alpha\beta$ mAbs. A large fraction of lymphocytes in LFVs from the antimesenteric side express IgM molecules (IgM⁺ LFVs), whereas only a small fraction of lymphocytes in LFVs from the non-antimesenteric side express IgM molecules (IgM⁻ LFVs). The ratios of $\alpha\beta$ T cells are comparable in the two types of LFVs

and isolated a tiny fragment of the small intestine containing one LFV by a technique described elsewhere.^{4,15} Lymphocytes isolated from LFVs that were located in tandem on the antimesenteric wall (Fig. 3b, c); i.e., IgM⁺ LFV, and those from LFVs localized throughout the mucosa (Fig. 3b, d); i.e., IgM⁻ LFV, were stained using anti-IgM and anti- $\alpha\beta$ -TCR mAbs, and subjected to flow cytometry. About 30% of the lymphocytes isolated from LFVs on the antimesenteric wall were IgM⁺, compared to less than 5% of those isolated from LFVs localized in other areas (Fig. 5). It also became evident that the composition of $\alpha\beta$ T cells was about 20%–30% for both IgM⁺ and IgM⁻ LFVs (Fig. 5). Thus, LFVs that are localized throughout the length of the antimesenteric wall of the small intestine from young adult rat contain a large number of IgM⁺ B cells. In the mouse small-intestinal mucosa, ILFs are found on the antimesenteric wall.¹⁵ Like mouse ILFs,¹⁵ these rat LFVs are located on the antimesenteric wall and contain B cells, suggesting that rat IgM⁺ LFVs are comparable to mouse ILFs. We also confirmed that, on day 13 of the postnatal period, IgM⁺ B cells were very few in number in both antimesenteric (Fig. 6a) and scattered (Fig. 6c) LFVs and that only a marginal number of $\alpha\beta$ T cells were detected in both types of LFVs (Fig. 6b, d). Overall, these results indicate that IgM⁺ LFVs in the rat develop between the ages of 13 days and 7 weeks.

In view of the finding that the cellular composition of LFVs changes with age, we investigated LFVs in 22-week-old rats. Clusters of IgM⁺ B cells (Fig. 7a) composed of anti-rat pan B-cell mAb-positive cells (Fig. 7b) were found not only in LFVs that were arranged linearly on the antimesenteric side but also in LFVs that were distributed randomly throughout the intestinal mucosa. Furthermore, IgM⁺ LFVs contained an area where the slightly larger cells were congregated, suggesting the development of a germinal center in these LFVs from aged rats. We therefore examined whether

such areas truly represented germinal centers, using PNA staining.¹⁶ This B-cell area turned out to be occupied by PNA⁺ cells, indicating the presence of a secondary follicle with a germinal center (Fig. 7c). Furthermore, B cells concentrated in the germinal center were found to contain a substantial number of IgA⁺ B cells (Fig. 7d).

The proliferation of rat LFVs was investigated by a technique of BrdU uptake, and BrdU⁺ cells were found in both IgM⁺ (Fig. 8a, b) and IgM⁻ (Fig. 8c, d) LFVs in 7-week-old rats, accounting for about 10% of cells (Fig. 8b, d). The ratio of BrdU⁺ cells was higher in LFVs than in rat thymic medulla (5%–10%), but lower than that in the thymic cortex (<30%). As might have been expected, numerous BrdU⁺ proliferating lymphocytes were observed in PPs from 7-week-old rats (Fig. 8e).

Discussion

In addition to PPs and MLNs, LFVs were reported to represent one of the organized GALTs compartmentalized in the rat small intestine.^{9,10} Although Mayrhofer and coworkers⁹ envisaged rat LFVs as a diffuse “gut thymus” and interpreted that T cells were generated in LFVs from precursors similar to triple-negative thymocytes, the details of these issues have remained to be explored to date. In this study, we aimed to investigate whether rat LFVs were comparable to mouse CPs, and whether any other rat GALTs comparable to mouse CPs were detectable.

In mice, the organogenesis of 6 to 12 PPs involves at least three distinct steps in the late embryonic stage,¹⁷ while the development of CPs³ and ILFs¹⁵ commences after birth. In rat small-intestinal mucosa, no lymphoid tissues that were morphologically identical to mouse CPs (lymphocytes distributed mainly in the crypt LP) were noted,^{9,10} but lymphocyte clusters that were clearly different from PPs were observed. As described above, Mayrhofer and co-workers⁹ have reported the existence of rat small-intestinal villi that are somewhat thicker in a longitudinal section than the surrounding classical villi. The villi were, in fact, distinguished by containing a LP that was replaced by closely packed lymphocytes; thus, these structures were named “LFVs”. In the present study, we confirmed the presence of LFVs in the GIT of Wistar rats and were able to show, for the first time, that, like mouse CPs, rat LFVs contained numerous c-kit⁺ and IL-7R⁺ undifferentiated lymphocytes.

The present results also clarified the existence of two types of LFVs in the rat small intestine; that is, those consisting of c-kit⁺ and IL-7R⁺ lymphocytes with and without IgM⁺ B cells. It was also noteworthy that the distribution and ratios of IgM⁺ and IgM⁻ LFVs changed




Fig. 6a-d. Immunohistochemical analysis of **a, b** antimesenteric and **c, d** scattered LFVs in young suckling Wistar rats. Expression of IgM (**a** and **c**) and TCR- $\alpha\beta$ (**b, d**) was assessed in LFVs from 13-day-old Wistar rats. Unlike LFVs in 7-week-old Wistar rats, LFVs on the antimesenteric side display only a few IgM⁺ cells on day 13 after birth (**a**)

with age. In rats at 7 to 8 weeks of age, most IgM⁺ LFVs were found on the antimesenteric wall, while IgM⁻ LFVs were found throughout the intestinal mucosa. At age 22 weeks, however, IgM⁺ LFVs were found throughout the intestinal mucosa and retained a germinal center. Mouse ILFs, which are composed of a large B-cell area, including a germinal center, are distributed predominantly on the antimesenteric wall.¹⁵ In ILFs from normal mice, the collection of B cells was surrounded by a layer of cells expressing c-kit and IL-7R molecules,¹⁵ and c-kit⁺ cells replaced B220⁺ B cells as the predominant population in ILFs from TCR- $\beta^{-/-}$, recombination-activating gene-2 (RAG-2)^{-/-}, and $\mu\text{m}^{-/-}$ mutant mice.¹⁵

According to Mayrhofer and colleagues,⁹ the phenotype of the major population of lymphocytes in rat LFVs remains CD3⁻, TCR- $\alpha\beta^{-}$, CD4⁻, CD8⁻, CD25⁺, CD43⁺, and CD161⁺. Thus, we have confirmed and extended their observations,⁹ by showing that the majority




Fig. 7a-d. Immunohistochemical characterization of LFVs from 22-week-old Wistar rats. In 22-week-old Wistar rats, lymphocytes in both antimesenteric (**a, b**) and scattered (not shown) LFVs are abundant in B cells. Some of these B cells were peanut agglutinin (PNA)⁺ (**c**) and IgA⁺ (**d**). These findings suggest that LFVs from aged Wistar rats are isolated lymphoid follicles (ILFs) with a germinal center




Fig. 8a-e. Bromodeoxyuridine (BrdU)-incorporated lymphocytes in IgM⁺ LFV, IgM⁻ LFV, and PP. After allowing 7-week-old Wistar rats to drink water containing BrdU for 20h, we prepared frozen sections of small intestine and subjected them to immunohistochemical analysis using mAbs. Distributions of IgM⁺ cells (**a, c**) and BrdU⁺ cells (**b, d**) were assessed in LFVs found on the antimesenteric side (**a, b**) and in other areas (**c, d**). PP displays many BrdU⁺ cells in the germinal center (**e**)

of lymphocytes congregating in rat LFVs are also c-kit⁺ and IL-7R⁺. Further, in agreement with what was observed by Mayrhofer and coworkers,⁹ $\alpha\beta$ ⁺ T cells appeared to be localized in the subepithelial regions of LFVs (Fig. 6b, f). However, we were unable to verify in the present study whether these rat LFVs containing undifferentiated lymphocytes represented clusters of extrathymic progenitor T cells, and this issue needs clarification in the future.

Acknowledgments. This work was supported by a Grant-in-Aid for Creative Scientific Research (13GS0015; Japan Society for the Promotion of Science); by a Grant-in-Aid for Scientific Research on Priority Areas A and a Grant-in-Aid for the Twenty-first Century Center of Excellence (COE) Program, entitled "Understanding and Control of Life's Function via Systems Biology" (Keio University), and by a Special Coordination Fund for Promoting Science and Technology (Ministry of Education, Culture, Sports, Science, and Technology), as well as by Health Science Research Grants (Ministry of Health, Labour, and Welfare).

References

1. Russell MW, Kilian M, Lamm ME. Biological activities of IgA. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienstock J, McGhee JR, editors. *Mucosal immunology*. 2nd ed. San Diego: Academic; 1999. p. 225–40.
2. Kelsall B, Strober W. Gut-associated lymphoid tissue. Antigen handling and T-lymphocyte responses. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienstock J, McGhee JR, editors. *Mucosal immunology*. 2nd ed. San Diego: Academic; 1999. p. 293–317.
3. Kanamori Y, Ishimaru K, Nanno M, Maki K, Ikuta K, Nariuchi H, et al. Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit⁺ IL-7R⁺ Thy1⁺ lympho-hemopoietic progenitors develop. *J Exp Med* 1996;184:1449–59.
4. Saito H, Kanamori Y, Takemori T, Nariuchi H, Kubota E, Takahashi-Iwanaga H, et al. Generation of intestinal T cells from progenitors residing in gut cryptopatches. *Science* 1998;280:275–8.
5. Oida T, Suzuki K, Nanno M, Kanamori Y, Saito H, Kubota E, et al. Role of gut cryptopatches in early extrathymic maturation of intestinal intraepithelial T cells. *J Immunol* 2000;164:3616–26.
6. Suzuki K, Oida T, Hamada H, Hitotsumatsu O, Watanabe M, Hibi T, et al. Gut cryptopatches: direct evidence of extrathymic anatomical sites for intestinal T lymphopoiesis. *Immunity* 2000;13:691–702.
7. Moghaddami M, Cummins A, Mayrhofer G. Lymphocyte-filled villi: comparison with other lymphoid aggregations in the mucosa of the human small intestine. *Gastroenterology* 1998;115:1414–25.
8. Naganuma M, Watanabe M, Kanai T, Iwao Y, Mukai M, Ishii H, et al. Characterization of structures with T-lymphocyte aggregates in ileal villi of Crohn's disease. *Am J Gastroenterol* 2002;97:1741–7.
9. Mayrhofer G, Moghaddami M, Murphy C. Lymphocyte-filled villi (LFV): non-classical organized lymphoid tissues in the mucosa of the small intestine. *Mucosal Immunol Update* 1999;7:9–13.
10. Mayrhofer G, Brooks A. Lymphopoiesis in lymphocyte-filled villi in the small intestine of the rat. *Clin Immunol Immunopathol* 1995;76:S55.
11. Masjedi M, Tivey DR, Thompson FM, Cummins AG. Activation of the gut-associated lymphoid tissue with expression of interleukin-2 receptors that peaks during weaning in the rat. *J Pediatr Gastroenterol Nutr* 1999;29:556–62.
12. Helgeland L, Brandtzaeg P, Rolstad B, Vaage JT. Sequential development of intraepithelial $\gamma\delta$ and $\alpha\beta$ T lymphocytes expressing CD8 $\alpha\beta$ in neonatal rat intestine: requirement for the thymus. *Immunology* 1997;92:447–56.
13. Ramanathan S, Marandi L, Poussier P. Evidence for the extrathymic origin of intestinal TCR $\gamma\delta$ ⁺ cells in normal rats and for an impairment of this differentiation pathway in BB rats. *J Immunol* 2002;168:2182–7.
14. Ishikawa H, Saito H, Suzuki K, Oida T, Kanamori Y. New gut associated lymphoid tissue "cryptopatches" breed murine intestinal intraepithelial T cell precursors. *Immunol Res* 1999;20:243–50.
15. Hamada H, Hiroi T, Nishiyama Y, Takahashi H, Masunaga Y, Hachimura S, et al. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. *J Immunol* 2002;168:57–64.
16. Rose ML, Birbeck MS, Wallis VJ, Forrester JA, Davies AJ. Peanut lectin binding properties of germinal centres of mouse lymphoid tissue. *Nature* 1980;284:364–6.
17. Yoshida H, Honda K, Shinkura R, Adachi S, Nishikawa S, Maki K, et al. IL-7 receptor α^+ CD3⁻ cells in the embryonic intestine induce the organizing center of Peyer's patches. *Int Immunol* 1999;11:643–55.

Is there a role for apheresis in gastrointestinal disorders?

Toshifumi Hibi* and Atsushi Sakuraba

T Hibi is Professor of Gastroenterology and Head of the Inflammatory Bowel Disease Center, and A Sakuraba is an Instructor at the Inflammatory Bowel Disease Center of Keio University, Japan.

APHERESIS is now a common therapeutic modality, with proven clinical benefits for several gastrointestinal disorders including inflammatory bowel disease (IBD),¹ pouchitis, intestinal Bechét's disease, alcoholic hepatitis and hepatitis C. Gastroenterologists have limited experience with apheresis, however, owing to the complexity of the process.

The etiology and pathogenesis of IBD remain obscure, but it is known that immunologic factors are involved and there is consensus that the inflamed mucosa of IBD patients are infiltrated by large numbers of inflammatory cells. The treatment of IBD with leukocyte apheresis is based on the hypothesis that removal of the circulating cells involved in intestinal inflammation will re-establish the balance between uncontrolled and controlled mucosal inflammation. The efficacy of leukocyte apheresis might not be restricted to cell removal, however, as contact activation of cells with the treatment apparatus or a change in proportions of regulatory T cells might also have immunomodulatory effects.

A single session of leukocyte apheresis removes approximately 3×10^9 – 10×10^9 granulocytes, which may be only ~10% of those circulating in the peripheral blood. A temporal decrease in the numbers of peripheral blood leukocytes and/or granulocytes is observed during the procedure, followed by a rapid return to the pretreatment level or higher. This rise in leukocyte numbers could be explained by the mobilization of leukocytes from the marginal pool. This results in a decrease in activated leukocytes and an increase in immature leukocytes in the peripheral blood. Under inflammatory conditions, the number and survival time of granulocytes are increased, and their serial removal could contribute to the anti-inflammatory effect of apheresis. Apheresis results in downregulation of several adhesion molecules and chemokine receptors on leukocytes, which might inhibit their migration to inflamed tissues. Furthermore, the capacity of peripheral leukocytes to produce proinflammatory cytokines is suppressed. The concomitant depletion of platelets

could also contribute to their immunomodulatory effects. Thus, the overall effects of apheresis might be due to reduced levels of activated leukocytes followed by an increase in the numbers of immature leukocytes; diminished leukocyte migration to the inflamed tissue; and a reduction in the levels of proinflammatory cytokines. Studies are needed to identify the exact mode of action of apheresis.

Several devices have been developed to improve the efficiency and simplify the process of leukocyte removal. Granulocyte and monocyte adsorption apheresis (GCAP), an adsorptive type of extracorporeal apheresis, is performed with the Adacolumn[®] apheresis system (Japan Immunoresearch Laboratory, Japan). The device contains cellulose-coated acetate beads, and adsorbs ~65% of granulocytes, 55% of monocytes, 2% of lymphocytes and a small number of platelets from the blood. A single procedure removes a total of $\sim 4.0 \times 10^9$ granulocytes and monocytes from the blood circulation. Leukocytapheresis (LCAP) performed with the Cellsorba[®] system (Asahi Medical, Japan), uses a filter consisting of nonwoven hollow fibers to trap leukocytes. LCAP nonselectively removes $\sim 13.0 \times 10^9$ leukocytes and 5.2×10^{11} platelets from the circulating blood during one session of treatment. The removal efficacy of leukocytes passing through the filter is close to 100%. In both procedures, blood inlet and outlet are via suitable veins in the bilateral forearms of the patient and small amounts of anticoagulants are added to the circulation. Sessions are performed at a flow rate of 30–50 ml/min for 1 h and weekly for 5–10 sessions. GCAP and LCAP have both been approved by the Japanese Government for the treatment of ulcerative colitis. LCAP is also approved for the treatment of rheumatoid arthritis.

Several uncontrolled trials of plasmapheresis² and lymphocyte apheresis³ have shown efficacy in active Crohn's disease; however, it has also been reported that the latter was unable to prevent relapse in those patients with corticosteroid-induced remission.⁴ The results of previous studies in Crohn's disease using the centrifugal

Correspondence

*Division of Gastroenterology
Department of Internal Medicine
School of Medicine
Keio University
35 Shinanomachi
Shinjuku
Tokyo 160-8582
Japan
thibi@sc.itc.keio.ac.jp

Received 14 January 2005

Accepted 6 April 2005

www.nature.com/clinicalpractice
doi:10.1038/npcgasthep0168

method to remove leukocytes are controversial. Studies of GCAP and LCAP in Crohn's disease are limited and only small pilot studies have been reported. Weekly treatment with GCAP or LCAP was, however, reported to be effective in >50% of treated patients.⁵

Nationwide multicenter trials have been carried out in Japan to assess the efficacy and safety of GCAP or LCAP compared with corticosteroid treatment in patients with active ulcerative colitis refractory to conventional medication.^{6,7} GCAP and LCAP showed clinical improvement in ~66% of patients, which was significantly higher than in patients treated with corticosteroids. In addition, significantly fewer adverse effects were seen in the GCAP and LCAP treatment groups; only mild adverse effects such as dizziness and nausea were observed in ~20% of the patients.

A double-blind controlled trial of LCAP showed that weekly treatment was more efficacious and safer than sham apheresis treatment; clinical improvement was shown in 80% of LCAP-treated patients compared with 33% of the sham-treated patients.⁸ A significant advantage was demonstrated, but the study was rather small (10 patients per treatment group), performed for active ulcerative colitis refractory to conventional drug therapy, and most patients were also receiving simultaneous corticosteroids.

The efficacy of GCAP in patients with active ulcerative colitis who were not on concomitant corticosteroids has also been reported.⁹ More than 80% of steroid-naïve patients showed a response to GCAP.

Weekly GCAP or LCAP induced remission in 3–4 weeks in ~66% of patients with moderate to severe active ulcerative colitis. Moreover, only minor side effects such as nausea, fever and rashes were observed in ~20% of the patients.

We have found that triweekly treatment with GCAP is more effective than weekly treatment, and therefore shortens the time needed to achieve remission without increasing the incidence of side effects (T Hibi and A Sakuraba, unpublished data). Furthermore, in a retrospective analysis, we found that weekly GCAP therapy was effective in patients who were steroid-refractory as well as in patients with steroid-dependent ulcerative colitis, thus allowing the dosage of corticosteroids to be reduced in these patients.¹⁰ In another preliminary study we confirmed that biweekly treatment of GCAP was as effective as 6-mercaptopurine in maintaining remission of ulcerative colitis. Several reports have also been published on the efficacy of

GCAP in pediatric patients with ulcerative colitis, for whom treatment with corticosteroids should ideally be avoided.

The standard therapeutic strategies used to treat IBD are reliant on drugs and carry with them associated adverse side effects. A treatment that is highly effective and safe has been long awaited and leukocyte apheresis might be the right candidate. This treatment should be considered as a nonpharmacologic adjunct to conventional therapy, however, as a single round of GCAP or LCAP will cost nearly US\$1,000. At present, its use should be limited to those patients who are steroid-refractory, or for whom corticosteroids are contraindicated.

Preliminary studies indicate that GCAP or LCAP is efficacious and safe in patients with IBD. To obtain maximum efficacy, we recommend that it should be performed triweekly for a total of 6–10 sessions. To prove the efficacy and assess the most efficient frequency of apheresis, further larger controlled studies should be conducted.

Supplementary information, in the form of a figure is available online on the *Nature Clinical Practice Gastroenterology & Hepatology* website.

References

- 1 Takazoe M *et al.* (2002) The present status and the recent development of the treatment for inflammatory bowel diseases: desirable effect of extracorporeal immunomodulation. *Ther Apher* **6**: 305–311
- 2 Holdstock GE *et al.* (1979) Plasmapheresis in Crohn's disease. *Digestion* **19**: 197–201
- 3 Bicks RO and Groshart KD (1989) The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. *J Clin Gastroenterol* **11**: 136–138
- 4 Lerebours E *et al.* (1994) Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives *Gastroenterology* **107**: 357–361
- 5 Fukuda Y *et al.* (2004) Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. *J Gastroenterol* **39**: 1158–1164
- 6 Simoyama T *et al.* (1999) Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis (Abstract). *Jpn J Apheresis* **18**: 117–131
- 7 Sawada K *et al.* (2003) Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. *Curr Pharm Des* **9**: 307–321
- 8 Sawada K *et al.* Leukocytapheresis in Ulcerative Colitis: Results of a Multicenter Double-blind Prospective Case-control Study with Sham Apheresis as Placebo Treatment. *Am J Gastroenterol*, in press
- 9 Suzuki Y *et al.* (2004) Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. *Dig Dis Sci* **49**: 565–571
- 10 Naganuma M *et al.* (2004) Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. *Inflamm Bowel Dis* **10**: 251–257

GLOSSARY

APHERESIS

The removal of blood from the body and withdrawal of a specific component. Blood is retransfused to the body once the process is complete

Competing interests

The authors declared they have no competing interests.

Abnormally Differentiated Subsets of Intestinal Macrophage Play a Key Role in Th1-Dominant Chronic Colitis through Excess Production of IL-12 and IL-23 in Response to Bacteria¹

Nobuhiko Kamada,* Tadakazu Hisamatsu,* Susumu Okamoto,* Toshiro Sato,* Katsuyoshi Matsuoka,* Kumiko Arai,* Takaaki Nakai,* Akira Hasegawa,* Nagamu Inoue,* Noriaki Watanabe,† Kiyoko S. Akagawa,‡ and Toshifumi Hibi^{2*}

Disorders in enteric bacteria recognition by intestinal macrophages (M ϕ) are strongly correlated with the pathogenesis of chronic colitis; however the precise mechanisms remain unclear. The aim of the current study was to elucidate the roles of M ϕ in intestinal inflammation by using an IL-10-deficient (IL-10^{-/-}) mouse colitis model. GM-CSF-induced bone marrow-derived M ϕ (GM-M ϕ) and M-CSF-induced bone marrow-derived M ϕ (M-M ϕ) were generated from bone marrow CD11b⁺ cells. M-M ϕ from IL-10^{-/-} mice produced abnormally large amounts of IL-12 and IL-23 upon stimulation with heat-killed whole bacteria Ags, whereas M-M ϕ from wild-type (WT) mice produced large amounts of IL-10 but not IL-12 or IL-23. In contrast, IL-12 production by GM-M ϕ was not significantly different between WT and IL-10^{-/-} mice. In ex vivo experiments, cytokine production ability of colonic lamina propria M ϕ (CLPM ϕ) but not splenic M ϕ from WT mice was similar to that of M-M ϕ , and CLPM ϕ but not splenic M ϕ from IL-10^{-/-} mice also showed abnormal IL-12p70 hyperproduction upon stimulation with bacteria. Surprisingly, the abnormal IL-12p70 hyperproduction from M-M ϕ from IL-10^{-/-} mice was improved by IL-10 supplementation during the differentiation process. These results suggest that CLPM ϕ and M-M ϕ act as anti-inflammatory M ϕ and suppress excess inflammation induced by bacteria in WT mice. In IL-10^{-/-} mice, however, such M ϕ subsets differentiated into an abnormal phenotype under an IL-10-deficient environment, and bacteria recognition by abnormally differentiated subsets of intestinal M ϕ may lead to Th1-dominant colitis via IL-12 and IL-23 hyperproduction. Our data provide new insights into the intestinal M ϕ to gut flora relationship in the development of colitis in IL-10^{-/-} mice. *The Journal of Immunology*, 2005, 175: 6900–6908.

Macrophages (M ϕ),³ the major population of tissue-resident mononuclear phagocytes, play key roles in bacterial recognition and elimination as well as in polarization of innate and adaptive immunities. M ϕ are activated by microbial pathogen-associated molecular patterns (PAMPs) through pattern-recognition receptors, such as TLRs (1, 2), and produce proinflammatory cytokines such as IL-12 and IL-23, thereby leading to development of Th1 immunity (3). Besides these classical antibacterial immune roles, it has recently become evident that M ϕ also play important roles in homeostasis maintenance, such as inflammation dampening, via production of anti-inflammatory cytokines such as IL-10 and TGF- β , debris scaveng-

ing, angiogenesis, and wound repair (4–6). IL-10 and IL-12 are two key players in these processes, usually acting in opposition, with IL-10 inhibiting IL-12 production. Therefore, loss of balance between IL-12 and IL-10 can lead to disproportionate pathology or immunosuppression.

Although precise etiologies of inflammatory bowel diseases (IBDs) including Crohn's disease and ulcerative colitis remain unclear, pathogenic roles of the gut flora in initiation and perpetuation of intestinal inflammation have been proposed (7). Recently, it has become evident that abnormal innate immune responses to bacteria are responsible for the pathogenesis of IBD. For instance, mutations in nucleotide-binding oligomerization domain (NOD)2 highly correlated with disease incidence in a substantial subgroup of patients with Crohn's disease (8, 9). NOD2 mutant M ϕ were reported to produce large amounts of IL-12 in response to stimulation with microbial components, compared with wild-type (WT) cells, and to promote Th1 immunity (10). Thus, disorders in bacterial recognition by M ϕ strongly correlate with pathogenesis of IBDs (11–13).

IL-10-deficient (IL-10^{-/-}) mice develop spontaneous chronic colitis and are widely used as a colitis animal model for human IBDs (14). IL-10^{-/-} mice show Th1 polarized immunity upon exposure to bacteria, whereas germfree conditions prevent development of intestinal inflammation (15), and treatment with antibiotics attenuates intestinal inflammation (16, 17). These facts suggest that enteric bacteria play essential roles in onset and development of colitis in IL-10^{-/-} mice, similar to human IBDs. Recently, the following pathogenic aspects of M ϕ in IL-10^{-/-} mice have been reported: APC such as M ϕ and dendritic cells (DC), from IL-10^{-/-} mice were potent activators of Th1 responses

*Department of Internal Medicine, School of Medicine, Keio University, †Department of Internal Medicine, Kitasato Institute Hospital, and ‡Department of Immunology, National Institute of Infectious Diseases, Tokyo, Japan

Received for publication June 14, 2005. Accepted for publication September 14, 2005.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by grants-in-aid from the Japanese Ministry of Education, Culture, and Science, the Japanese Ministry of Labor, Health, and Welfare, Keio University, and Keio University Medical Fund.

² Address correspondence and reprint requests to Dr. Toshifumi Hibi, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinano machi, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail address: thibi@sc.itc.keio.ac.jp

³ Abbreviations used in this paper: M ϕ , macrophage; WT, wild type; DC, dendritic cell; IBD, inflammatory bowel disease; NOD, nucleotide-binding oligomerization domain; BM, bone marrow; M-M ϕ , M-CSF-induced BM-derived M ϕ ; GM-M ϕ , GM-CSF-induced BM-derived M ϕ ; PGN, peptidoglycan; MDP, muramyl-dipeptide; PAMP, pathogen-associated molecular pattern; MOI, multiplicity of infection; CBA, cytometric beads array; CLPM ϕ , colonic lamina propria macrophage.

from naive or immune T cells (18, 19); M ϕ from IL-10^{-/-} mice were hyperreactive to microbial components (20); and M ϕ depletion prevented chronic colitis in IL-10^{-/-} mice (21). Based on these reports, M ϕ and DC are considered to play key roles in the pathogenesis of colitis in IL-10^{-/-} mice, although mechanisms for bacterial recognition by APC that induces a Th1 bias and development of intestinal inflammation remain unclear. Previous studies suggested that IL-12 was crucial for development of colitis in IL-10^{-/-} mice because mice deficient for both IL-10 and IL-12p40 showed no intestinal inflammation, and treatment with anti-IL-12p40 Abs markedly reduced intestinal inflammation (22, 23). Until now, however, how IL-10 deficiency affects IL-12 production from M ϕ in mice has not been thoroughly analyzed.

In the present study, we examined whether IL-10-deficient conditions affected differentiation and functions of bone marrow (BM)-derived M ϕ subsets and intestinal M ϕ , and investigated how bacteria recognition by M ϕ induced a Th1 polarization and intestinal inflammation in IL-10^{-/-} mice. We found that M-CSF-induced BM-derived M ϕ (M-M ϕ) and intestinal M ϕ , but not GM-CSF-induced BM-derived M ϕ (GM-M ϕ) or splenic M ϕ from IL-10^{-/-} mice showed abnormal hyperproduction of IL-12 and IL-23 upon stimulation with bacteria. More importantly, our results suggested that endogenous IL-10 played an essential role in differentiation of the anti-inflammatory M ϕ subset induced by M-CSF.

Materials and Methods

Reagents

Recombinant mouse GM-CSF, M-CSF, and IL-10 were purchased from R&D Systems. Gel filtration grade LPS (*Escherichia coli* O111:B4), muramyl-dipeptide (MDP), and *Staphylococcus aureus* peptidoglycan (PGN) were obtained from Sigma-Aldrich. Pam₃CSK₄ and *E. coli* ssDNA were obtained from InvivoGen.

Bacteria heat-killed Ags

A Gram-negative nonpathogenic strain of *E. coli* (25922; American Type Culture Collection (ATCC)) was cultured in Luria-Bertani medium, and a Gram-positive strain of *Enterococcus faecalis* (29212; ATCC) was cultured in brain-heart infusion medium. Bacteria were harvested and washed twice with ice-cold PBS. Then, bacterial suspensions were heated at 80°C for 30 min, washed, resuspended in PBS, and stored at -80°C. Complete killing was confirmed by 72 h incubation at 37°C on plate medium.

Mice

Specific pathogen-free WT C57BL/6J mice were purchased from Charles River Breeding Laboratories. WT and IL-10^{-/-} (C57BL/6J background) mice were housed under specific pathogen-free conditions at the animal center of Kitasato Institute Hospital and Keio University (Tokyo, Japan). All experiments using mice were approved by and performed according to the guidelines of the animal committee of Keio University and Kitasato Institute Hospital.

Preparation of BM-derived M ϕ

BM cells were isolated from femora of 7- to 12-wk-old mice. After separation of BM mononuclear cells by gradient centrifugation, CD11b⁺ cells were purified using a magnetic cell separation system (MACS; Miltenyi Biotec) with anti-mouse CD11b microbeads. To generate BM-derived GM-M ϕ and M-M ϕ , CD11b⁺ cells (5 × 10⁵ cells/ml) were cultured for 7 days with GM-CSF (20 ng/ml) and M-CSF (20 ng/ml), respectively. In some experiments, to determine effects of IL-10 during differentiation of M-M ϕ , BM CD11b⁺ cells from IL-10^{-/-} mice were cultured with M-CSF and various concentrations of exogenous IL-10. After differentiation, cells were washed three times with HBSS to remove residual IL-10.

Flow cytometry analysis

Day 7 BM-derived GM-M ϕ and M-M ϕ were harvested with EDTA and washed with ice-cold PBS. Then, cells were preincubated with 1 μ g/ml mAb CD16/CD32 to block Fc γ R, and stained with mAbs CD11b, Gr-1, TLR4/MD2, or TLR2 (all from eBiosciences), mAbs CD80 or CD86 (both

from BD Pharmingen) or their isotype control Abs for 20 min at 4°C. After staining, cells were washed with PBS, stained with propidium iodide, and analyzed using a FACSCalibur (BD Pharmingen). The CellQuest software was used for data analysis.

Activation of BM-derived M ϕ by PAMPs

Day 7 BM-derived GM-M ϕ and M-M ϕ were harvested, plated on 96-well tissue culture plates (1 × 10⁵ cells/well) in RPMI 1640 medium supplemented with 10% FBS, antibiotics, and 20 ng/ml GM-CSF or M-CSF, and incubated for 12–16 h. Before each experiment, M ϕ were washed three times with HBSS (Sigma-Aldrich) to completely remove secreted or supplemented cytokines from the supernatant, and were stimulated with either LPS (100 ng/ml), PGN (2 μ g/ml), Pam₃CSK₄ (500 ng/ml), *E. coli* ssDNA (10 μ g/ml), MDP (10 μ g/ml), or heat-killed bacteria (multiplicity of infection (MOI) = 100) for 24 h. Culture supernatants were collected, passed through 0.22- μ m pore size filters, and then stored at -80°C until the cytokine assay.

Isolation of colonic lamina propria M ϕ (CLPM ϕ) and splenic M ϕ

Lamina propria mononuclear cells were isolated using a modified protocol as previously described (25). Briefly, mice were sacrificed, and colonic tissues were removed. Isolated colons were washed with HBSS, dissected into small pieces, and incubated in HBSS containing 2.5% FBS and 1 mM DTT (Sigma-Aldrich) to remove any mucus. Then, the pieces were incubated in HBSS containing 1 mM EDTA (Sigma-Aldrich) twice for 20 min each at 37°C, washed three times with HBSS, and incubated in HBSS containing 1 mM collagenase type IV (Sigma-Aldrich) for 2 h at 37°C. Digested tissues were filtered and washed twice with HBSS. Isolated cells were resuspended in 40% Percoll (Pharmacia Biotech), layered onto 75% Percoll, and centrifuged at 2000 rpm for 20 min. Cells were recovered from the interphase and washed with PBS. CLPM ϕ and splenic M ϕ were purified by positive selection from lamina propria mononuclear cells or unfractionated splenocytes using MACS CD11b microbeads (Miltenyi Biotec) as previously described (24, 26).

Activation of M ϕ by whole bacteria Ags

BM-derived M ϕ , and isolated CLPM ϕ and splenic M ϕ were plated on 96-well tissue culture plates (1 × 10⁵ cells/well) in RPMI 1640 medium supplemented with 10% FBS and antibiotics, and stimulated by heat-killed bacterial Ags (MOI = 100) for 24 h at 37°C. Culture supernatants were collected, passed through a 0.22- μ m pore size filter, and stored at -80°C until the cytokine assay.

Cytokine assay

A mouse inflammatory cytometric beads array (CBA) kit (BD Pharmingen) was used for cytokine measurements, according to the manufacturer's instructions. Samples were analyzed using a FACSCalibur (BD Pharmingen).

Quantitative RT-PCR

After 8 h of stimulation by bacterial Ags, total RNA was isolated from M ϕ using an RNeasy Mini kit (Qiagen). In some experiments, RNA was isolated from colonic tissues and spleen. cDNA was synthesized with OmniScript reverse transcriptase (Qiagen). For quantitative RT-PCR, TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assays for murine IL-12p35, IL-12p40, IL-23p19, M-CSF, GM-CSF, and β -actin (Applied Biosystems) were used. PCR amplifications were conducted in a thermocycler DNA Engine (OPTICON2; MJ Research). Cycling conditions for PCR amplification were 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

Statistical analysis

Statistical significance of differences between two groups was tested using a Student's *t* test. For comparison of more than two groups, ANOVA was used. If the ANOVA was significant, Dunnett's multiple comparison test or Scheffe's test were used as a post hoc test.

Results

GM-M ϕ and M-M ϕ derived from BM CD11b⁺ cells from IL-10^{-/-} mice do not differ significantly from those derived from WT mice in morphology and cell surface Ag expressions

When BM-derived CD11b⁺ cells from WT mice were cultured in M-CSF or GM-CSF for 7 days, they showed morphological

changes characteristic of M ϕ such as increases in size and adherence, and were stained with nonspecific esterase (data not shown). As shown in Fig. 1A, GM-CSF and M-CSF induced differentiation of BM CD11b⁺ cells into two distinct subsets of adherent M ϕ , which corresponded to human GM-M ϕ and M-M ϕ (27). GM-M ϕ derived from BM CD11b⁺ cells had a rounded morphology and possessed dendrites, similar to DCs. In contrast, M-M ϕ derived

from BM CD11b⁺ cells had an elongated spindle-like morphology. FACS analysis revealed that GM-M ϕ expressed higher levels of MHC class II molecules and costimulatory molecules CD80 compared with M-M ϕ (Fig. 1B and Table I). Expression of Gr-1 was also different between them; i.e., GM-M ϕ but not M-M ϕ expressed Gr-1 (Fig. 1B and Table I). However, CD11c, a DC marker, was not expressed on both M ϕ (data not shown).

Next, we compared the two M ϕ subsets derived from IL-10^{-/-} BM CD11b⁺ cells with those from WT BM CD11b⁺ cells. As shown in Fig. 1A, both GM-M ϕ and M-M ϕ from IL-10^{-/-} BM CD11b⁺ cells showed normal morphological characteristics. Flow cytometric analysis further revealed that these M ϕ subsets from IL-10^{-/-} mice did not differ from those in WT mice in their cell surface Ag expressions (Fig. 1B and Table I). These results suggest that GM-M ϕ and M-M ϕ from IL-10^{-/-} mice are similar to those in WT mice, at least in terms of morphology and cell surface Ag expression.

BM-derived M-M ϕ from WT mice show an anti-inflammatory phenotype in response to PAMPs and whole bacterial Ags

To determine the immunological responses of GM-M ϕ and M-M ϕ from WT mice to PAMPs stimulation, M ϕ were stimulated with various kinds of PAMPs for 24 h, and production levels of IL-12p70 and IL-10 in culture supernatant were measured. As shown in Fig. 2A, none of the stimuli tested induced IL-12p70 production from both M ϕ in WT mice. In contrast, the TLR4 ligand LPS, TLR2 ligands PGN and Pam₃CSK₄, and TLR9 ligand *E. coli* ssDNA induced IL-10 production by these M ϕ , although the amounts produced were higher in M-M ϕ compared with GM-M ϕ . The NOD2 ligand MDP did not induce either IL-12p70 or IL-10 in either subset from WT mice.

Next, we examined the effects of whole bacterial Ags on these M ϕ . In contrast to stimulation with PAMPs, stimulation of GM-M ϕ with heat-killed *E. coli* and *E. faecalis* induced IL-12p70 production (Fig. 2B). However, M-M ϕ from WT mice did not produce IL-12p70, but did produce large amounts of IL-10 in response to the whole bacterial Ags (Fig. 2B). These results suggested that M-M ϕ , but not GM-M ϕ , in WT mice act as anti-inflammatory M ϕ in the recognition of bacteria.

BM-derived M-M ϕ but not GM-M ϕ from IL-10^{-/-} mice reveal abnormal hyperproduction of IL-12 and IL-23 in response to whole bacterial Ags

We next examined the effects of PAMPs and whole bacteria Ags on GM-M ϕ and M-M ϕ from IL-10^{-/-} mice. In contrast to the results obtained from M ϕ in WT mice, IL-10^{-/-} M ϕ produced IL-12p70 by stimulation with LPS or Pam₃CSK₄, although the amounts were very low, and no significant differences were observed between GM-M ϕ and M-M ϕ (Fig. 3A). The use of 10-fold higher concentrations of these PAMPs did not induce higher levels of IL-12p70 either (data not shown).

Upon whole bacteria stimulation, such as with heat-killed *E. coli* and *E. faecalis*, GM-M ϕ from IL-10^{-/-} mice produced similar levels of IL-12p70 to WT GM-M ϕ , although they lacked IL-10 production ability (Fig. 3B). Surprisingly, in contrast to WT M-M ϕ , M-M ϕ from IL-10^{-/-} mice produced significantly large amounts of IL-12p70 upon stimulation with whole bacterial Ags (Fig. 3B). In addition, a lower dose of the whole bacteria Ag (MOI = 10) also induced abnormally large IL-12p70 production (data not shown).

To further confirm this abnormal IL-12p70 hyperproduction by IL-10^{-/-} M-M ϕ , gene transcriptions of IL-12p35, p40, and IL-23p19 were analyzed using real-time quantitative PCR. Results revealed that basal expressions of these genes before stimulation




FIGURE 1. In vitro differentiated M ϕ from WT and IL-10^{-/-} mice do not differ in morphology and surface marker expressions. A, BM CD11b⁺ cells from WT and IL-10^{-/-} mice were polarized into M ϕ with GM-CSF or M-CSF for 7 days. B, Polarized M ϕ from WT and IL-10^{-/-} mice (KO) were stained with the indicated mAbs and analyzed by flow cytometry. Profiles of specific Ab staining (shaded histograms) and staining with isotype controls (open histograms) are shown. Data shown are representative of five independent experiments.

Table I. Expression of surface Ags on BM-derived different subsets of macrophage^a

	ΔMFI			
	WT		KO	
	GM-Mφ	M-Mφ	GM-Mφ	M-Mφ
CD11b	1174.2 ± 155.5*	509.5 ± 58.7	1229.7 ± 15.5*	388.2 ± 58.5
Gr-1	93.1 ± 3.4*	0.0 ± 0.0	63.7 ± 7.6*	0.0 ± 0.0
CD80	290.4 ± 34.2*	73.4 ± 27.5	383.0 ± 4.1*	38.6 ± 2.5
CD86	14.5 ± 1.6	36.2 ± 8.1	26.7 ± 0.9	35.9 ± 3.4
TLR2	348.6 ± 18.6	342.4 ± 118.8	386.0 ± 48.8	220.0 ± 4.4
TLR4/MD2	7.6 ± 2.1	18.4 ± 0.8	8.7 ± 4.3	18.8 ± 4.8
MHC-II	20.6 ± 3.7*	1.7 ± 0.4	24.4 ± 5.9*	1.5 ± 0.3

^a Data indicated as ΔMFI (geometric mean fluorescence intensity (MFI) of each Ab staining minus MFI of control IgG staining), and are expressed as mean ± SEM of five independent experiments. *, $p < 0.01$ compared with M-Mφ (Scheffé's test)

were almost undetectable in GM-Mφ and M-Mφ from both WT and IL-10^{-/-} mice (data not shown). Upon stimulation with *E. coli*, their expressions were detected in GM-Mφ from both WT and IL-10^{-/-} mice, and expression levels in GM-Mφ from IL-10^{-/-} mice were ~3- to 4-fold higher than levels in WT mice (Fig. 3C). In contrast, expression levels of those genes were quite different in M-Mφ from WT and IL-10^{-/-} mice. These transcripts remained at very low levels in WT M-Mφ even after stimulation; however, IL-10^{-/-} M-Mφ showed markedly high expressions of IL-12 and IL-23 genes (Fig. 3C).

These results suggest that GM-Mφ can produce IL-12 and IL-23 in response to bacterial stimuli, whereas M-Mφ cannot produce these cytokines but rather produce anti-inflammatory cytokine IL-10. The results also suggested that endogenous IL-10 strongly contributes to inhibition of IL-12p70 production in M-Mφ but not GM-Mφ. Thus, IL-10^{-/-} M-Mφ may contribute to Th1 polarization by producing IL-12p70 upon stimulation with bacteria.

Exogenous IL-10 supplementation at the time of stimulation with whole bacteria Ag inhibits abnormal IL-12p70 hyperproduction by IL-10^{-/-} M-Mφ

Because M-Mφ, but not GM-Mφ, from IL-10^{-/-} mice showed abnormal IL-12 and IL-23 hyperproduction in response to stimulation with *E. coli*, we further examined how absence of IL-10 led to IL-12 and IL-23 hyperproduction from M-Mφ. M-Mφ from IL-10^{-/-} mice were stimulated with heat-killed bacterial Ags concomitant with a supplementation of exogenous IL-10 (Fig. 4A). Abnormal IL-12p70 hyperproduction by M-Mφ from IL-10^{-/-} mice was completely suppressed by exogenous IL-10 in a dose-dependent manner (Fig. 4B). In addition, IL-10 had similar inhibitory effects on productions of other proinflammatory cytokines (TNF-α and IL-6) from IL-10^{-/-} Mφ. These findings were consistent with a previous report showing that IL-10 inhibited production of several proinflammatory cytokines by Mφ, including IL-12 (28). These results suggest that IL-10 inhibits the production of proinflammatory cytokines by M-Mφ in response to stimulation with whole bacteria Ags.

Exogenous IL-10 supplementation during the differentiation process attenuates abnormal IL-12p70 hyperproduction by IL-10^{-/-} M-Mφ

As described, IL-10 production by M-Mφ in response to bacteria is important for suppression of IL-12p70 production, as well as for other cytokine productions; however, how IL-10 acts on the differentiation process of BM CD11b⁺ cells still remains unclear. Therefore, we examined the role of IL-10 in differentiation of M-Mφ from BM CD11b⁺ cells. BM CD11b⁺ cells from IL-10^{-/-}

mice were differentiated into M-Mφ with M-CSF in the presence of exogenous IL-10. Polarized M-Mφ were thoroughly washed to remove any residual IL-10, and then stimulated by heat-killed *E. coli* without exogenous IL-10 (Fig. 5A). Interestingly, M-Mφ differentiated from IL-10^{-/-} mice in the presence of M-CSF and exogenous IL-10 was unable to induce large amounts of IL-12p70 production in response to stimulation with *E. coli*, although exogenous IL-10 was removed from the culture supernatant before bacterial Ags were added (Fig. 5B).

Contrary to the production of IL-12p70, the other proinflammatory cytokines (TNF-α and IL-6) were only partially or not significantly suppressed by IL-10 supplementation during the differentiation process. Moreover, consistent with IL-12p70 results, levels of IL-12p35, IL-12p40, and IL-23p19 mRNA transcripts were significantly reduced in IL-10^{-/-} M-Mφ differentiated in the presence of exogenous IL-10 (Fig. 5C). These results suggest that endogenous IL-10 is an essential cytokine for functional differentiation of M-Mφ, especially for maturation of the phenotype as anti-inflammatory Mφ, which cannot produce IL-12p70 while producing large amounts of IL-10.

CLPMφ but not splenic Mφ show functional similarity to BM-derived M-Mφ in the production of IL-10 and IL-12

It became evident that in vitro differentiated M-Mφ, but not GM-Mφ, from IL-10^{-/-} mice showed abnormal responses to whole bacteria Ags. Hence, we further analyzed CLPMφ from WT and IL-10^{-/-} mice to investigate how intestinal Mφ act in vivo and contribute to trigger and develop Th1-dominant inflammation in IL-10^{-/-} mice. CLPMφ from WT mice did not produce IL-12p70 upon stimulation with heat-killed *E. coli*, but instead produced large amounts of IL-10, and the levels were similar to those of BM-derived M-Mφ (Fig. 6A). In contrast, CLPMφ from IL-10^{-/-} mice produced significantly larger amounts of IL-12p70 in response to stimulation with the bacteria, and levels were similar to those of BM-derived M-Mφ from IL-10^{-/-} mice (Fig. 6A). In contrast to CLPMφ, abnormal IL-12p70 hyperproductions by bacteria were not observed in splenic Mφ from IL-10^{-/-} mice, although TNF-α induction levels were similar to those of CLPMφ (Fig. 6A). Similar results were obtained when CLPMφ from WT and IL-10^{-/-} mice were stimulated with heat-killed *E. faecalis* (data not shown).

These results suggest that CLPMφ revealed a functional similarity to that of M-Mφ, that CLPMφ from WT mice act as anti-inflammatory Mφ via production of large amounts of IL-10, and that CLPMφ from IL-10^{-/-} mice contribute to the development of Th1-dominant colitis via the abnormal hyperproduction of IL-12p70.




FIGURE 2. BM-derived M-M ϕ from WT mice reveal an anti-inflammatory phenotype in response to PAMPs and whole bacterial Ags. **A**, Polarized GM-M ϕ and M-M ϕ (1×10^5 cells) from WT mice were stimulated with LPS (100 ng/ml), PGN (2 μ g/ml), Pam₃CSK₄ (500 ng/ml), *E. coli* ssDNA (10 μ g/ml), or MDP (10 μ g/ml) for 24 h. The amounts of IL-12p70 and IL-10 in the culture supernatants were measured using a CBA kit. Data are expressed as the mean \pm SEM from five independent experiments for LPS, PGN, Pam₃CSK₄, and ssDNA and three independent experiments for MDP. **B**, GM-M ϕ and M-M ϕ (1×10^5 cells) from WT mice were stimulated with a heat-killed Gram-negative strain of *E. coli* or a heat-killed Gram-positive strain of *E. faecalis* (MOI = 100). Data are expressed as the mean \pm SEM from seven independent experiments. N.D., Not detected.

Therefore, we next assessed the expression of M-CSF and GM-CSF in colonic tissues and spleen because M-CSF and GM-CSF are different in their activity to induce anti-inflammatory M ϕ as described. M-CSF to GM-CSF expression level ratios in murine colonic tissues were dramatically higher than in spleen (Fig. 6B).

These results demonstrate that M-CSF rich environment in colonic tissues may contribute the differentiation of intestinal M ϕ into anti-inflammatory M-M ϕ phenotype.




FIGURE 3. BM-derived M-M ϕ from IL-10^{-/-} mice produced large amounts of IL-12p70 in response to whole bacteria Ags. **A**, GM-CSF- or M-CSF-induced M ϕ (1×10^5 cells) from IL-10^{-/-} mice (KO) were stimulated with LPS (100 ng/ml), PGN (2 μ g/ml), Pam₃CSK₄ (500 ng/ml), *E. coli* ssDNA (10 μ g/ml), or MDP (10 μ g/ml) for 24 h. Data are expressed as the mean \pm SEM from five independent experiments for LPS, PGN, Pam₃CSK₄, ssDNA and three independent experiments for MDP. **B**, GM-CSF- or M-CSF-induced M ϕ (1×10^5 cells) from WT and mice were stimulated with heat-killed *E. coli* or *E. faecalis* (MOI = 100) for 24 h. Data are expressed as the mean \pm SEM from seven independent experiments. N.D., Not detected. ***, $p < 0.001$ compared with WT M ϕ (Student's t test). **C**, GM-M ϕ and M-M ϕ (1×10^5 cells) were stimulated by heat-killed *E. coli* (MOI = 100) for 8 h. The gene expressions of IL-12p35, IL-12p40, and IL-23p19 were analyzed by real-time quantitative PCR and normalized by the amount of β -actin transcripts. Data indicate the fold expression compared with WT mice and are expressed as the mean \pm SEM from three independent experiments.

Discussion

The results we present revealed that CLPM ϕ and M-CSF-induced M-M ϕ in WT mice produce large amounts of IL-10, but not IL-12 and IL-23 upon stimulation with whole bacteria Ags. In contrast, GM-CSF-induced GM-M ϕ in WT mice produce IL-12 and IL-23 despite of IL-10 production. In contrast, we first demonstrated that CLPM ϕ and BM-derived M-M ϕ in IL-10^{-/-} mice produced abnormal large amounts of IL-12 and IL-23 upon stimulation with bacteria, but splenic M ϕ and BM-derived GM-M ϕ in IL-10^{-/-} mice were not significantly different from those in WT mice. These




FIGURE 4. Exogenous IL-10 prevents the production of proinflammatory cytokines by M-Mφ from IL-10^{-/-} mice. *A*, Schema of the experiment. *B*, M-Mφ (1 × 10⁵ cells) from WT and IL-10^{-/-} mice (KO) were stimulated with heat-killed *E. coli* (MOI = 100) for 24 h with or without various concentrations of exogenous IL-10. The amounts of IL-12p70, TNF-α, and IL-6 in the culture supernatants were measured using a CBA kit. Data are expressed as the mean ± SEM from three independent experiments. N.D., Not detected. **, *p* < 0.01 compared with IL-10^{-/-} Mφ without IL-10 supplementation (Dunnett's test).

results indicate that CLPMφ usually acts as anti-inflammatory Mφ, however, CLPMφ in IL-10^{-/-} mice play key roles in Th1-dominant chronic colitis through excess production of IL-12 and IL-23.

In the present study, we demonstrated that GM-Mφ and M-Mφ were different not only in morphology or cell surface Ag expression but also in the production of proinflammatory cytokines IL-12, IL-23, and anti-inflammatory cytokine IL-10 in response to heat-killed bacteria, such as *E. coli* and *E. faecalis*. Such differences in cytokine production by Mφ generated under the influence of M-CSF and GM-CSF were also reported in human monocyte-derived Mφ. Human monocyte-derived GM-Mφ show potent Ag-presenting functions, produce IL-12p40 and IL-23p19, but none to low levels of IL-10 in response to mycobacteria and their components, and promote development of Th1 immunity (27, 29, 30). In contrast, human monocyte-derived M-Mφ show low Ag-presenting activity and produce large amounts of IL-10 but no IL-12 or IL-23 (27, 29, 30). Thus, it is considered that these two subsets of Mφ play opposite roles both in mice and humans; GM-Mφ act as proinflammatory and M-Mφ act as anti-inflammatory Mφ in response to bacteria. In contrast to mice BM-derived GM-Mφ, human monocyte-derived GM-Mφ can produce IL-23 but not IL-12 (29). Reasons for differences between our mice study and previously reported human studies might be attributed to differences in the type of cells used (mouse BM-derived Mφ and human monocyte-derived Mφ) or in the stimulus used (*E. coli* and *E. faecalis* vs mycobacteria and their components).

Because the intestinal mucosa of the gut is always exposed to numerous enteric bacteria including both pathogenic and non-pathogenic bacteria, it is considered that the gut may possess regulatory mechanisms preventing excessive inflammatory responses. In fact, it was previously reported that human intestinal Mφ does




FIGURE 5. IL-10 supplementation during the differentiation process of M-Mφ improves the abnormal IL-12 production upon stimulation with whole bacterial Ags. *A*, Schema of the experiment. *B*, BM CD11b⁺ cells from IL-10^{-/-} mice (KO) were differentiated with 20 ng/ml M-CSF and various concentrations of exogenous IL-10 (0–100 ng/ml) for 7 days. The M-Mφ were harvested, seeded at 1 × 10⁵ cells/well, and incubated for 15–16 h. The cells were washed three times to remove any residual cytokines and then stimulated by heat-killed *E. coli* (MOI = 100) for 24 h. The amounts of IL-12p70, TNF-α, and IL-6 in the culture supernatants were measured using a CBA kit. Data are expressed as the mean ± SEM from 10 independent experiments. N.D., Not detected. *, *p* < 0.05; **, *p* < 0.01 compared with IL-10^{-/-} Mφ differentiated without IL-10 supplementation (Dunnett's test). *C*, BM CD11b⁺ cells from IL-10^{-/-} (KO) were polarized with M-CSF (20 ng/ml) alone or M-CSF plus IL-10 (20 ng/ml). The polarized Mφ were stimulated by heat-killed *E. coli* (MOI = 100) for 8 h. The mRNA expressions are shown as relative percentages of the levels in knockout mice without IL-10 supplementation. Data are expressed as the mean ± SEM from five independent experiments. **, *p* < 0.01; ***, *p* < 0.001; #, *p* < 0.0001 compared with levels in KO mice without IL-10 supplementation (Student's *t* test).

not express innate response receptors (31, 32). Although these cells retained their phagocytic and bacteriocidal functions, they did not produce proinflammatory cytokines in response to several inflammatory stimuli such as microbial components (31, 32). Thus, recent studies have suggested that Mφ located in the intestinal mucosa play important roles in the maintenance of intestinal homeostasis by protecting the host from foreign pathogens (33) and regulating excess immune responses to enteric bacteria (32).




FIGURE 6. CLPM ϕ , but not splenic M ϕ , from IL-10^{-/-} mice produce a large amount of IL-12 upon stimulation with whole bacterial Ags. **A**, CLPM ϕ and splenic M ϕ were isolated from WT and IL-10^{-/-} mice (KO). M ϕ were seeded at 1×10^5 cells/well and incubated with or without heat-killed *E. coli* (MOI = 100) for 24 h. The amounts of IL-12p70, IL-10, and TNF- α in the culture supernatants were measured using a CBA kit. Data are expressed as the mean \pm SEM from six independent experiments. N.D., Not detected; N.S., not significant. **, $p < 0.01$ (Scheffé's test). **B**, Expression of M-CSF and GM-CSF in murine tissues from WT mice. Data are expressed as the ratio of M-CSF to GM-CSF expression.

Consistent with these human studies, our present study shows that CLPM ϕ in WT mice does not produce proinflammatory cytokines IL-12 and IL-23, and produced just few amounts of TNF- α and IL-6 (data not shown) but large amounts of IL-10 upon stimulation with heat-killed *E. coli* and *E. faecalis* Ags. Thus, CLPM ϕ may act as anti-inflammatory M ϕ in vivo, when encountering bacteria. These behaviors of CLPM ϕ were very similar to those of in vitro differentiated M-M ϕ . In agreement with this observation, our present study showed that M-CSF to GM-CSF expression level ratios in murine colonic tissues were higher than in other organs, such as spleen. These results suggest that M-CSF-rich conditions in colonic tissues might play an important role in differentiation of CLPM ϕ as anti-inflammatory M ϕ . In accordance with this idea, recent studies suggested that M-CSF is an essential growth factor for development of intestinal M ϕ . The number of intestinal M ϕ in M-CSF-deficient *op/op* mice was significantly decreased (33, 34),

and M-CSF was expressed in the lamina propria in the human intestine (35).

IL-10^{-/-} mice develop Th1 polarized spontaneous chronic colitis and are widely used as a colitis animal model for human IBDs (14). It has been reported that enteric bacteria play essential roles in onset and development of colitis in IL-10^{-/-} mice, similar to human IBDs (15). However, functional roles of enteric bacteria in development of colitis in IL-10^{-/-} mice have not been identified. We demonstrated in this study that bacteria induce abnormal production of proinflammatory cytokines IL-12 and IL-23 from intestinal M ϕ , but not splenic M ϕ in IL-10^{-/-} mice. Because IL-12 and IL-23 are key cytokines, which induce Th1 immune responses, and IL-12 plays a critical role for the development of colitis in IL-10^{-/-} mice (22, 23), these abnormal responses of intestinal M ϕ in IL-10^{-/-} mice to bacteria may cause Th1 polarization and development of colitis.

In the present study, only stimuli from whole bacteria, but not from PAMPs could induce the production of IL-12p70. IL-12 bioactive form consisted of p35-p40 heterodimer, in differentiated M ϕ from BM CD11b⁺ cells. In general, TLR ligands such as LPS only induce IL-12p40 subunits, but fail to induce IL-12p70 production from M ϕ without IFN- γ costimulation (36, 37). Consistent with this, we also demonstrated that GM-M ϕ and M-M ϕ produced none or just low levels of IL-12p70 in response to stimulation with various TLR ligands. In contrast, whole bacterial Ags induced IL-12p70 production by GM-M ϕ in WT and IL-10^{-/-} mice, and by M-M ϕ in IL-10^{-/-} mice without IFN- γ . Moreover, intestinal M ϕ from IL-10^{-/-} mice also produced high levels of IL-12p70 in response to stimulation with whole bacteria Ags without IFN- γ , but did not induce IL-12p70 in response to LPS alone (data not shown). These findings imply that TLR ligands and whole bacteria may activate IL-12p70 production through distinct mechanisms. Because whole bacteria are internalized into M ϕ by phagocytosis, it is possible that cell surface receptors involved in phagocytosis are different from TLRs, and can stimulate signaling for IL-12p70 production, and/or internalized bacteria stimulate IL-12p70 production via an intracellular recognition pathway. These are important observations that will help in understanding the pathogenesis of enteric bacteria in development of colitis in IL-10^{-/-} mice, and clarification of these points are underway.

M ϕ and DCs can produce both IL-12 and IL-10, but IL-10 is known to inhibit the production of not only IL-12 but also other proinflammatory cytokines through several transcriptional regulations (38–40). In fact, in the present study, we demonstrated that abnormal IL-12p70 hyperproduction by M-M ϕ in IL-10^{-/-} mice were completely suppressed by exogenous IL-10 supplementation concomitant with bacterial stimulation. These results indicated that the lack of IL-10 production by bacterial stimulation may account for the abnormal IL-12p70 hyperproduction by IL-10^{-/-} M-M ϕ . In the present study, however, we found that IL-10 also plays a novel role for the differentiation of M ϕ with anti-inflammatory phenotype. We demonstrated that abnormal IL-12p70 production by IL-10^{-/-} M-M ϕ in response to stimulation with bacteria was significantly reduced by supplementation with IL-10 during the differentiation process from BM cells to M-M ϕ . Interestingly, the effect of IL-10 on the differentiation of M ϕ differs from that on the concomitant stimulation with bacteria. In the former case, only IL-12p70 production was significantly reduced, and TNF- α and IL-6 productions were suppressed just a little or not at all. In contrast, in the latter case, not only IL-12p70 but also other proinflammatory cytokines (TNF- α and IL-6) were completely suppressed. These results indicated that, in anti-inflammatory M ϕ subsets, IL-12 was regulated during the differentiation process by endogenous IL-10, but TNF- α and IL-6 were not regulated in this process. Thus, endogenous IL-10, which is induced during differentiation of M-M ϕ , functionally regulates M ϕ to acquire an anti-inflammatory phenotype such as the hypoproduction of IL-12. Moreover, abnormally differentiated BM-derived M-M ϕ and CLPM ϕ in IL-10^{-/-} mice may show an abnormal response to bacteria, produce extraordinary amounts of IL-12 and IL-23, and contribute to the pathogenesis of colitis in IL-10^{-/-} mice. Similarly to these results, we previously demonstrated that endogenous IL-10 plays a key role in phenotype determination of M-M ϕ in humans (27, 41), and IL-10 is produced during the differentiation of monocyte-derived M-M ϕ , but not of GM-M ϕ (30). In human IBDs, monocytes obtained from some patients who have Crohn's disease did not differentiate normally with M-CSF stimulation (T. Hisamatsu, unpublished observation). This observation suggests the possibility that M-M ϕ from patients with Crohn's disease

show an abnormal phenotype and contribute to the pathogenesis of intestinal inflammation.

In conclusion, results of the present study demonstrate that BM-derived M-M ϕ and intestinal M ϕ show an anti-inflammatory phenotype, which involves the production of large amounts of IL-10, but a failure to produce IL-12 and IL-23 upon stimulation with bacteria, and intestinal M ϕ may play important roles in gut homeostasis. However, IL-10 deficiency during differentiation of these M ϕ altered their characteristics into a proinflammatory phenotype, which was characterized by the production of huge amounts of IL-12 and IL-23 after bacteria recognition. Thus, these abnormal responses of intestinal M ϕ upon the bacteria may contribute to Th1 polarization, and cause chronic colitis via IL-12 and IL-23 hyperproductions. Our data provide new insights into the intestinal M ϕ to gut flora relationship in the development of colitis in IL-10^{-/-} mice.

Acknowledgments

We thank Drs. A. Nakazawa, T. Yajima, H. Chinen, and T. Kobayashi for helpful discussions and critical comments. We dedicate this paper to the memory of Akira Hasegawa, who passed away during this investigation.

Disclosures

The authors have no financial conflict of interest.

References

- Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. *Annu. Rev. Immunol.* 20: 197–216.
- Sieling, P. A., and R. L. Modlin. 2002. Toll-like receptors: mammalian "taste receptors" for a smorgasbord of microbial invaders. *Curr. Opin. Microbiol.* 5: 70–75.
- Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. *Nat. Rev. Immunol.* 3: 133–146.
- Gordon, S. 2003. Alternative activation of macrophages. *Nat. Rev. Immunol.* 3: 23–35.
- Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol.* 25: 677–686.
- Mosser, D. M. 2003. The many faces of macrophage activation. *J. Leukocyte Biol.* 73: 209–212.
- Podolsky, D. K. 2002. Inflammatory bowel disease. *N. Engl. J. Med.* 347: 417–429.
- Ogura, Y., D. K. Bonen, N. Inohara, D. L. Nicolae, F. F. Chen, R. Ramos, H. Britton, T. Moran, R. Karaliuskas, R. H. Duerr, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 411: 603–606.
- Hugot, J. P., M. Chamaillard, H. Zouali, S. Lesage, J. P. Cezard, J. Belaiche, S. Almer, C. Tysk, C. A. O'Morain, M. Gassull, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 411: 599–603.
- Watanabe, T., A. Kitani, P. J. Murray, and W. Strober. 2004. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. *Nat. Immunol.* 5: 800–808.
- Mahida, Y. R. 2000. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. *Inflamm. Bowel Dis.* 6: 21–33.
- Rogler, G. 2004. Update in inflammatory bowel disease pathogenesis. *Curr. Opin. Gastroenterol.* 20: 311–317.
- Eckmann, L. 2004. Innate immunity and mucosal bacterial interactions in the intestine. *Curr. Opin. Gastroenterol.* 20: 82–88.
- Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75: 263–274.
- Sellon, R. K., S. Tonkonogy, M. Schultz, L. A. Dieleman, W. Grenther, E. Balish, D. M. Rennick, and R. B. Sartor. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. *Infect. Immun.* 66: 5224–5231.
- Madsen, K. L., J. S. Doyle, M. M. Tavemini, L. D. Jewell, R. P. Rennie, and R. N. Fedorak. 2000. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. *Gastroenterology* 118: 1094–1105.
- Hoentjen, F., H. J. Harmsen, H. Braat, C. D. Torrice, B. A. Mann, R. B. Sartor, L. A. Dieleman, K. L. Madsen, J. S. Doyle, M. M. Tavemini, et al. 2003. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. *Gut* 52: 1721–1727.
- Igietseme, J. U., G. A. Ananaba, J. Bolier, S. Bowers, T. Moore, T. Belay, F. O. Eko, D. Lyn, and C. M. Black. 2000. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. *J. Immunol.* 164: 4212–4219.

19. Hickman, S. P., J. Chan, and P. Salgame. 2002. *Mycobacterium tuberculosis* induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization. *J. Immunol.* 168: 4636–4642.
20. Takakura, R., T. Kiyohara, Y. Murayama, Y. Miyazaki, Y. Miyoshi, Y. Shinomura, and Y. Matsuzawa. 2002. Enhanced macrophage responsiveness to lipopolysaccharide and CD40 stimulation in a murine model of inflammatory bowel disease: IL-10-deficient mice. *Inflamm. Res.* 51: 409–415.
21. Watanabe, N., K. Ikuta, K. Okazaki, H. Nakase, Y. Tabata, M. Matsuura, H. Tamaki, C. Kawanami, T. Honjo, and T. Chiba. 2003. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. *Dig. Dis. Sci.* 48: 408–414.
22. Kullberg, M. C., A. G. Rothfuchs, D. Jankovic, P. Caspar, T. A. Wynn, P. L. Gorelick, A. W. Cheever, and A. Sher. 2001. *Helicobacter hepaticus*-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. *Infect. Immun.* 69: 4232–4241.
23. Davidson, N. J., S. A. Hudak, R. E. Lesley, S. Menon, M. W. Leach, and D. M. Rennick. 1998. IL-12, but not IFN- γ plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. *J. Immunol.* 161: 3143–3149.
24. Hirofani, T., P. Y. Lee, H. Kuwata, M. Yamamoto, M. Matsumoto, I. Kawase, S. Akira, and K. Takeda. 2005. The nuclear I κ B protein I κ BNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. *J. Immunol.* 174: 3650–3657.
25. Kanai, T., M. Watanabe, A. Okazawa, T. Sato, M. Yamazaki, S. Okamoto, H. Ishii, T. Totsuka, R. Iiyama, R. Okamoto, et al. 2001. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. *Gastroenterology* 121: 875–888.
26. Chelvarajan, R. L., S. M. Collins, J. M. Van Willigen, and S. Bondada. 2005. The unresponsiveness of aged mice to polysaccharide antigen is a result of a defect in macrophage function. *J. Leukocyte Biol.* 77: 503–512.
27. Akagawa, K. S. 2002. Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. *Int. J. Hematol.* 76: 27–34.
28. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. *Annu. Rev. Immunol.* 19: 683–765.
29. Verreck, F. A., T. de Boer, D. M. Langenberg, M. A. Hoeve, M. Kramer, E. Vaisberg, R. Kastelein, A. Kolk, R. de Waal-Malefyt, and T. H. Ottenhoff. 2004. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. *Proc. Natl. Acad. Sci. USA* 101: 4560–4565.
30. Mochida-Nishimura, K., K. S. Akagawa, and E. A. Rich. 2001. Interleukin-10 contributes development of macrophage suppressor activities by macrophage colony-stimulating factor, but not by granulocyte-macrophage colony-stimulating factor. *Cell. Immunol.* 214: 81–88.
31. Smith, P. D., L. E. Smythies, M. Mosteller-Barnum, D. A. Sibley, M. W. Russell, M. Merger, M. T. Sellers, J. M. Orenstein, T. Shimada, M. F. Graham, and H. Kubagawa. 2001. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. *J. Immunol.* 167: 2651–2656.
32. Smythies, L. E., M. Sellers, R. H. Clements, M. Mosteller-Barnum, G. Meng, W. H. Benjamin, J. M. Orenstein, and P. D. Smith. 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. *J. Clin. Invest.* 115: 66–75.
33. Pull, S. L., J. M. Doherty, J. C. Mills, J. I. Gordon, and T. S. Stappenbeck. 2005. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. *Proc. Natl. Acad. Sci. USA* 102: 99–104.
34. Cecchini, M. G., M. G. Dominguez, S. Mocci, A. Wetterwald, R. Felix, H. Fleisch, O. Chisholm, W. Hofstetter, J. W. Pollard, and E. R. Stanley. 1994. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. *Development* 120: 1357–1372.
35. Klebl, F. H., J. E. Olsen, S. Jain, and W. F. Doe. 2001. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. *J. Pathol.* 195: 609–615.
36. Liu, J., S. Cao, L. M. Herman, and X. Ma. 2003. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)- γ -primed IL-12 production by IFN regulatory factor 1. *J. Exp. Med.* 198: 1265–1276.
37. Oliveira, M. A., G. M. Lima, M. T. Shio, P. J. Leenen, and I. A. Abrahamsohn. 2003. Immature macrophages derived from mouse bone marrow produce large amounts of IL-12p40 after LPS stimulation. *J. Leukocyte Biol.* 74: 857–867.
38. Hoentjen, F., R. B. Sartor, M. Ozaki, and C. Jobin. 2005. STAT3 regulates NF- κ B recruitment to the IL-12p40 promoter in dendritic cells. *Blood* 105: 689–696.
39. Zhou, L., A. A. Nazarian, and S. T. Smale. 2004. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. *Mol. Cell. Biol.* 24: 2385–2396.
40. Kuwata, H., Y. Watanabe, H. Miyoshi, M. Yamamoto, T. Kaisho, K. Takeda, and S. Akira. 2003. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF- α production in macrophages. *Blood* 102: 4123–4129.
41. Hashimoto, S., M. Yamada, K. Motoyoshi, and K. S. Akagawa. 1997. Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10. *Blood* 89: 315–321.

ORIGINAL ARTICLE

Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy

TAKAYUKI MATSUMOTO¹, MITSUO IIDA¹, YUTAKA KOHGO², AKIMICHI IMAMURA³, KAZUO KUSUGAMI⁴, HIROSHI NAKANO⁵, YOSHIHIDE FUJIYAMA⁶, TOSHIYUKI MATSUI^{1,7} & TOSHIFUMI HIBI⁸

¹Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, ²Third Department of Internal Medicine, Asahikawa College of Medicine, Asahikawa, ³Division of Gastroenterology, Sapporo Kosei General Hospital, Sapporo, ⁴First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, ⁵Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, ⁶Department of Internal Medicine, Shiga University of Medical Science, Otsu, ⁷Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, and ⁸Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

Abstract

Objective. The aim of this investigation was to elucidate retrospectively the therapeutic effect of infliximab in patients with active Crohn's disease (CD) under nutritional therapy. **Material and methods.** Using a review of the clinical records in 24 nationwide institutions specializing in inflammatory bowel disease, the short-term effect of infliximab in 97 patients with active CD was retrospectively investigated. The Crohn's disease activity index (CDAI) at baseline and after 2 weeks of a single infliximab administration (5 mg/kg) was compared among patients under total parenteral nutrition (TPN group, $n=36$), those following an elemental or polymeric diet (EN group, $n=49$) and those without TPN and EN (NN group, $n=12$). A decrease in $CDAI \geq 70$ or a CDAI value < 150 at 2 weeks was regarded as effective. **Results.** There was no difference in CDAI at baseline among the three groups. In each group, CDAI decreased significantly (from 250 (195–290) [median (interquartiles)] to 152 (123–233) in the TPN group, $p < 0.0001$; from 259 (200–325) to 180 (130–238) in the EN group, $p < 0.0001$; from 278 (222–291) to 164 (132–196) in the NN group, $p = 0.003$). Infliximab was effective in 63.9% of patients in the TPN group, in 55.1% of those in the EN group and in 75% of the NN group. There was no statistical difference in efficacy among the three groups ($p = 0.4$). Multivariate logistic regression analysis revealed younger age to be a significant factor related to the efficacy of infliximab. **Conclusions.** Infliximab is effective in patients with CD under TPN or EN. Age at infliximab administration may be predictive of response to infliximab.

Key Words: Crohn's disease, infliximab, nutritional therapy

Introduction

Infliximab, a chimeric antibody to tumor necrosis factor (TNF)- α , has become widely accepted as an effective agent for the treatment of active and refractory Crohn's disease (CD) [1]. It has also been shown that infliximab prolongs remission in CD [2,3]. Based on an accumulation of a large number of clinical trials, guidelines for the clinical use of infliximab in patients with CD have been defined [4,5]. Recently, various clinical parameters and medications for the prediction of the efficacy

have been identified for the use of infliximab [6–10].

In Japan, however, total parenteral nutrition (TPN) and enteral nutrition (EN) have been approved as primary therapies for the treatment of active CD [11]. These nutritional therapies have been shown to have a therapeutic effect equal to or less than that of steroids [12,13]. In addition, recent investigations confirmed that EN is effective in CD, regardless of nitrogen sources [14–16]. However, the effect of infliximab under nutritional therapy has not been examined previously.

On the basis of the results of a preliminary multicenter trial of infliximab in Japanese patients with CD [17], the agent has become available in Japan. In this study, we retrospectively investigated the effect of infliximab on Japanese patients with CD from a multicenter database in order to elucidate the short-term effect of infliximab under TPN or EN, and to identify the clinical characteristics predictive of response to infliximab in Japanese patients with CD.

Material and methods

Subjects

This study was performed retrospectively by reviewing the clinical records in 24 institutions specializing in the treatment of chronic inflammatory bowel diseases in Japan (see Appendix). Since the Japanese Ministry of Labor and Welfare approved infliximab as a therapeutic agent in June 2002, the practical use and the side effects of the drug have been monitored by Tanabe Seiyaku Corporation (Tokyo, Japan) during a period from November 2002 to March 2003. The purpose of monitoring was to specify the incidence of adverse events and infusion reaction of infliximab in Japanese patients with CD. The clinical data of 138 subjects, in whom infliximab was administered at a dose of 5 mg/kg, were obtained from the attending physicians (Figure 1). In 25 patients, the Crohn's disease activity index (CDAI) values prior to treatment were less than 150. In 16 patients, TPN or EN was changed to the other nutritional treatment or was discontinued after infliximab administration. These 41 patients were excluded from the analysis. The remaining 97 patients were the subjects of the present investiga-




Figure 1. Scheme for recruitment of study subjects. Clinical data of 138 patients were collected; 41 patients were excluded from the analysis because they had inactive disease or they were treated with different nutritional therapies during observation. Thirty-six patients were continuously treated with total parenteral nutrition (TPN group) and 49 patients with enteral nutrition (EN group). Twelve patients were not given any nutritional treatment (NN group).

tion; 85 patients were continuously treated with TPN or EN during a period from at least 1 week prior to and 2 weeks after infliximab. The other 12 patients were not treated with either TPN or EN. We directly contacted each attending physician and the following clinical items were reviewed.

Parenteral and enteral nutrition

The TPN group comprised 36 subjects who were treated with intravenous hyperalimentation through catheterization in the superior vena cava at a dose of over 1500 kcal/day. Similarly, the EN group comprised 49 subjects in whom either an elemental or polymeric diet of over 1500 kcal/day was applied. The formula of EN included an elemental diet (Elental; Ajinomoto Farma Co., Tokyo, Japan) and polymeric diet (Ensure Liquid; Abot Japan Co., Racall; Otsuka Seiyaku Co., Tokyo, Japan). Twelve patients without TPN or EN treatment were classified as the NN group.

Data collection

Information collected included age, gender, duration and site of CD, prior surgery, intestinal complications (stricture and fistula), concomitant medications and smoking habits.

The location of the disease was divided into three types: small intestinal disease only, colonic disease only and both small and large intestinal disease. Intestinal stricture was defined as an obvious intestinal stricture demonstrated by radiography or endoscopy, regardless of abdominal symptoms. Fistulous disease was regarded to be positive when there was a fistulous tract between the intestine or between the intestine and the skin, or when there was a perianal fistula. Patients without any fistulous disease were categorized as having inflammatory disease. As for the prior surgery, intestinal resection and strictureplasty were counted as positive findings.

Treatments with corticosteroids and immunosuppressive drugs were analyzed separately. When any dose of prednisolone was administered during 2 weeks after infliximab treatment, the subject was regarded to be positive for steroid treatment. Similarly, the use of thiopurines (azathioprine or 6-mercaptopurine) was judged to be positive for immunosuppressive drugs. None of the subjects was treated with methotrexate.

Disease activity and treatment efficacy

Determination of response was based on the CDAI [18], which was calculated using a review of the clinical records of each patient. CDAI was determined prior to and 2 weeks after infliximab

administration. A decrease in CDAI ≥ 70 was regarded as a response, and a CDAI value < 150 after 2 weeks as clinical remission. The overall efficacy of infliximab was determined to be effective when a patient showed a response or achieved clinical remission. Otherwise, infliximab was regarded to be ineffective.

Statistical analysis

Non-parametric variables were expressed as frequencies and percentages, and the associations between them were tested among the groups by χ^2 test or Fisher's exact probability test, when appropriate. Parametric variables were expressed as medians (interquartile ranges) and compared among groups using the Kruskal-Wallis test. When there was a significant difference among the groups, the value was compared between any two groups using the Mann-Whitney U-test. In each treatment group, CDAI was compared between prior to and after 2 weeks of infliximab using the Wilcoxon's signed-rank test. A stepwise logistic regression analysis was applied to evaluate significant variables, which affected the efficacy of infliximab. All these statistics were calculated with the two-tailed test, using statistic software (SPSS version 10.0 for windows; SPSS Japan Inc., Tokyo, Japan). Probabilities of less than 0.05 were considered to be significant.

Results

Demographic data

The study included 97 patients, with a male predominance (21 F, 76 M, age range 17–53 years). Time interval from diagnosis of CD until infliximab administration ranged from 1 to 29 years. Eight patients had small intestinal disease only and 16 patients had large intestinal disease only, while the remaining 73 patients had both small and large intestinal involvement. Ninety-six patients were being treated with oral 5-ASA. In addition, 26 patients were being treated with prednisolone and 22 with thiopurines; 55 of 97 patients had a prior history of intestinal resection. None of the patients had been previously treated with infliximab.

A comparison of the demographic data of the TPN, EN and NN groups is presented in Table I. As indicated in the table, age, gender, time interval from onset, and site of involvement were no different between groups. However, there were differences in the frequency of fistulous disease and application of prednisolone. Fistulous disease was less frequent in the TPN group than in the other two groups, and prednisolone was more frequently applied in the NN

group than in the other groups. Infusion reaction was recorded in three patients (one patient in the EN group and two patients in the TPN group). The infusion reaction, however, did not lead to discontinuance of infliximab. Thus, all 97 patients completed a course of infliximab.

Changes in disease activity

CDAI at baseline was 250 (195–290) in the TPN group, 259 (200–325) in the EN group, and 278 (222–291) in the NN group. There was no difference in CDAI at baseline among the groups ($p = 0.628$).

Individual changes in CDAI between baseline and 2 weeks after infliximab are indicated in Figure 2. CDAI after 2 weeks was 152 (123–233) in the TPN group, 180 (130–238) in the EN group, and 164 (132–196) in the NN group. In each group, CDAI decreased significantly 2 weeks after treatment with infliximab ($p < 0.0001$ in the TPN and EN groups, and $p = 0.003$ in the NN group).

Assessment of therapeutic efficacy

Response rate, remission rate, and therapeutic efficacy are compared in Figure 3. Forty-six of 97 patients responded to infliximab. The response rate was 44.4% (16 of 36 patients) in the TPN group, 46.9% (23 of 49 patients) in the EN group, and 58.3% (7 of 12 patients) in the NN group. Although the value was the highest in the NN group, there was no statistical difference in response rate among the groups ($p = 0.7$).

Thirty-six patients achieved remission 2 weeks after infliximab administration. The remission rate showed the highest value (17 of 36 patients, 47.2%) in the TPN group, followed by the NN group (4 of 12 patients, 33.3%) and the EN group (15 of 49 patients, 30.6%). As well as response rate, remission rate was not different among the three groups ($p = 0.28$).

Overall, infliximab was effective in 59 of 97 patients (60.8%). There was no difference in efficacy of infliximab among the TPN group (23 of 36 patients, 63.9%), the EN group (27 of 49 patients, 55.1%) and the NN group (9 of 12 patients, 75%) ($p = 0.4$).

Comparisons of the therapeutic efficacy of infliximab among the TPN, EN, and NN groups of inflammatory or fistulous disease are presented in Table II. No difference in response rate or remission rate was observed in either inflammatory disease or fistulous disease. In inflammatory disease, the efficacy rate was higher in the TPN group than in the other two groups ($p = 0.02$), but this trend in efficacy rate was not found in fistulous disease.

Table I. Demographic data of the patients.

Clinical variables	TPN group (n = 36)	EN group (n = 49)	NN group (n = 12)	p-value
Age (years) ^a	33 (30–40)	33 (27–38)	32 (30–34)	0.13
Sex (female/male)	5/31	11/38	5/7	0.36
Duration of disease (years) ^a	8 (6–13)	9 (4–15)	8 (5–11)	0.92
Site of involvement				0.55
Small intestine only	3 (8%)	4 (8%)	1 (8%)	
Small and large intestine	25 (69%)	40 (82%)	8 (67%)	
Large intestine only	8 (22%)	5 (10%)	3 (25%)	0.31
Intestinal complication				
Stricture	15 (42%)	21 (43%)	6 (50%)	0.60
Fistula	13 (36%)	37 (76%)	8 (67%)	0.01
Medication				
5-ASA*	36 (100%)	48 (98%)	12 (100%)	0.61
Prednisolone	7 (19%)	12 (24%)	7 (58%)	0.027
Thiopurines	9 (25%)	10 (20%)	3 (25%)	0.86
Prior intestinal resection	23 (64%)	26 (53%)	6 (50%)	0.53
CDAI at baseline ^a	250 (195–290)	259 (200–325)	278 (222–291)	0.62

Abbreviations: TPN = total parenteral nutrition; EN = enteral nutrition; NN = without TPN or EN; CDAI = Crohn's disease activity index.

^aData are expressed as medians (interquartile value).

*5-aminosalicylic acid.

Comparison of patients' characteristics according to the efficacy of infliximab

Comparison of the clinical features of CD classified by the efficacy of infliximab is presented in Table III. Patients in whom infliximab was effective were of younger age at time of administration than those in whom infliximab was ineffective. However, duration of CD until infliximab administration was not different between the two groups. There were trends towards more frequent application of thiopurines and less frequent intestinal stricture in patients who responded to infliximab than in those who did not. The application of TPN or EN was not different according to the efficacy of infliximab. As has been shown in the table, the age at the time of infliximab administration was the only variable that slightly but significantly affected the efficacy (odds ratio (OR); 1.09, 95% confidence interval (CI); 1.01–1.18; $p=0.028$). Thiopurines (OR; 3.44, 95% CI; 0.92–12.82, $p=0.066$) and stricture (OR; 0.039, 95% CI; 0.14–1.09, $p=0.073$) were insignificant variables for the efficacy of infliximab. Neither TPN nor EN contributed to the efficacy of infliximab.

Discussion

Elemental or polymeric diet has been used as primary therapy in patients with active CD [13–16,19–21]. Whereas two meta-analyses showed steroids to be superior to enteral nutrition in inducing remission in patients with active CD [12,22], another recent meta-analysis in the field of pediatrics

revealed no such difference in therapeutic efficacy [23]. More recent clinical trials have confirmed elemental diet and polymeric diet to be equally effective in the treatment of active CD [15,16]. Although treatment with infliximab is indicated for CD, which is refractory to steroids [4], the effect of infliximab on the disease under nutritional therapy has not been investigated to date. The aim in this investigation was to determine whether the short-term effect of infliximab is different according to simultaneous nutritional therapy. The results of the present investigation indicated that CDAI decreased significantly 2 weeks after a single dose of infliximab, that the effect was independent of simultaneous




Figure 2. Comparison of individual Crohn's disease activity index (CDAI) values between baseline and 2 weeks after infliximab administration. CDAI decreased from 250 (195–290) (median (interquartile range)) to 152 (123–233) in the total parenteral nutrition (TPN) group, from 259 (200–325) to 180 (130–238) in the enteral nutrition (EN) group, and from 278 (222–291) to 164 (132–196) in the no nutritional treatment (NN) group.